Search results
Added:
3 days ago
Added:
9 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
SGLTi and GLP-1 in HF
Added:
10 months ago
Review Article
Added:
1 year ago
In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the…
View more
Added:
1 year ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design…
View more
Added:
5 months ago
EASD 2025 - Simultaneous finerenone and empagliflozin was a safe therapy option in patients with diabetes and chronic kidney disease (CKD).Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) joins us to discuss safety and efficacy findings from a double-blind, randomised, prespecified subanalysis of CONFIDENCE (NCT05254002), investigating simultaneous finerenone and…
View more
Added:
7 months ago
Source:
Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and…
View more
Added:
7 months ago
Source:
Radcliffe CVRM
A new study has explored the underlying mechanisms by which semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH).¹ The research, which combined analysis of a phase 2 clinical trial with preclinical models, identified a unique proteomic signature associated with treatment and suggests that…
View more
Added:
5 days ago
Source:
Cardiac Failure Review Journal
Delays in diagnosis and treatment for patients with suspected heart failure (HF) in the community can lead to preventable hospitalisations and deaths. A new modelling study by Dr Kieran Docherty and colleagues suggests that early initiation of disease-modifying therapies in select patients at the time of an elevated natriuretic peptide test could significantly reduce these adverse outcomes…
View more
Added:
1 year ago